Clinical Trial

GI Innovation and GI Biome Advance to the Semi-finals of XPRIZE Healthspan with Anti-Aging Potential of GI-102 and GIB-7 Combination Therapy

GI Innovation and GI Biome have been selected as a Top 40 semi-finalist in the XPRIZE Healthspan competition among 600 registered teams from 58…

8 months ago

Aranscia Acquires Spesana

Electronic Health Systems Pioneer Carla Balch Joins Aranscia's Executive Leadership Team HOUSTON, May 12, 2025 /PRNewswire/ --  Aranscia, a global…

8 months ago

Avant Technologies and Ainnova Tech Begin Acquisition Talks Ahead of FDA Pre-Submission Meeting

LAS VEGAS, May 12, 2025 /PRNewswire/ -- Avant Technologies, Inc. (OTCQB: AVAI) ("Avant" or the "Company"), and its JV partner, Ainnova…

8 months ago

$101M XPRIZE HEALTHSPAN AWARDS FIRST MILESTONE WINNERS DRIVING TOWARD REVOLUTIONARY HEALTHY AGING ADVANCES

Over 600 competing teams from 58 countries entered global competition. Teams with a broad range of potential solutions for healthspan…

8 months ago

Hemostemix Closes Private Placement of USD $336,500 at $0.295 per Share

Calgary, Alberta--(Newsfile Corp. - May 12, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company"),…

8 months ago

MEDVi Under Review: Best GLP-1 Semaglutide & Terzepatide Compound Solution for Personalized Weight Loss

A Comprehensive Review of MEDVi’s Personalized GLP-1 Weight Loss Solutions Featuring Affordable Compounded Semaglutide and Tirzepatide Delivered via TelehealthNew York,…

8 months ago

Akero Therapeutics and HistoIndex Present New Analyses of Phase 2b HARMONY Trial in Oral and Poster Presentations at the EASL Congress 2025

Analysis of EFX results with AI-based digital pathology underscores the potential value in evaluating histopathology response Data contribute to growing…

8 months ago

Applied Therapeutics Announces Acceptance of Late-Breaking Abstract for Oral Presentation at the Peripheral Nerve Society 2025 Annual Meeting

Late-breaking oral presentation to include full 12-month clinical data from INSPIRE registrational Phase 3 trial in addition to topline 18-month…

8 months ago

Anivive’s Dr. Edward Robb Presents Innovative Valley Fever Vaccine Research at World Vaccine Congress 2025

WASHINGTON, May 9, 2025 /PRNewswire/ -- Dr. Edward Robb, Chief Strategy Officer, Anivive Lifesciences presented their pioneering research update on…

8 months ago